Small Peptides as Modulators of Serine Proteases

Area of Science:

• Biochemistry
• Pharmacology
• Medicinal Chemistry

Background:

• Serine proteases are crucial in physiological and pathological processes, making them key therapeutic targets.
• Current treatments involve suppressing aberrant protease activity, but new modulators are needed.
• Peptides (10-20 residues) offer a unique drug profile, combining properties of small molecules and biologics.

Purpose of the Study:

• To review recent advancements in peptide-based inhibitors targeting serine proteases.
• To discuss strategies for improving the in vivo performance of peptide drugs.
• To highlight the therapeutic potential of peptide inhibitors for serine protease-related diseases.

Main Methods:

• Literature review of recent developments in peptide inhibitor research.
• Analysis of studies focusing on enhancing peptide pharmacokinetic properties.
• Synthesis of information on the efficacy and specificity of peptide inhibitors.

Main Results:

• Peptide inhibitors demonstrate potent serine protease inhibition with high specificity, comparable to monoclonal antibodies.
• Various strategies exist to enhance peptide plasma half-life and bioavailability.
• Overcoming pharmacokinetic limitations is crucial for clinical translation.

Conclusions:

• Peptide-based inhibitors represent a promising therapeutic strategy for diseases involving serine proteases.
• Further research into optimizing peptide drug delivery will accelerate clinical applications.
• This review provides a roadmap for developing effective serine protease inhibitors.